Back to Browse Journals » Research and Reports in Urology » Volume 3

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer

Authors Solanki AA, Liauw SL

Published Date June 2011 Volume 2011:3 Pages 95—104

DOI http://dx.doi.org/10.2147/RRU.S14245

Published 15 June 2011

Abhishek A Solanki, Stanley L Liauw
Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL, USA

Abstract: Brachytherapy and external beam radiotherapy are effective and commonly used treatment modalities in men with localized prostate cancer. In this review, we explore the role of radiation therapy in the curative management of prostate cancer, including the use of conformal therapeutic techniques to allow for the escalation of radiation doses to tumor, along with the use of combined radiation and hormonal therapy to enhance disease outcomes in men with aggressive disease. We also review the possible anticancer role of HMG-CoA reductase inhibiting agents (statins) in men with prostate cancer. Laboratory evidence suggests that statins may have antineoplastic effects when used alone and may sensitize cells to radiation therapy when given in combination. We explore the biologic basis for an anticancer effect and the clinical evidence suggesting statins may aid in improving outcomes with radiation therapy for localized prostate cancer.

Keywords:
HMG-CoA reductase inhibitors, statins, radiotherapy, prostate cancer

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Readers of this article also read:

Self-management: keeping it simple with “Flo”

Cund A, Birch-Jones JL, Kay M, Connolly P

Nursing: Research and Reviews 2015, 5:49-55

Published Date: 2 March 2015

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer

Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V

OncoTargets and Therapy 2014, 7:2205-2213

Published Date: 28 November 2014

Specialized mouse embryonic stem cells for studying vascular development

Glaser DE, Burns AB, Hatano R, Medrzycki M, Fan Y, McCloskey KE

Stem Cells and Cloning: Advances and Applications 2014, 7:79-88

Published Date: 7 October 2014

Antifungal cyclic peptides from the marine sponge Microscleroderma herdmani [Corrigendum]

Zhang X, Jacob MR, Ranga Rao R, Wang YH, Agarwal AK, Newman DJ, Khan IA, Clark AM, Li XC

Research and Reports in Medicinal Chemistry 2013, 3:9-10

Published Date: 13 March 2013

Stereotactic body radiation therapy via helical tomotherapy to replace brachytherapy for brachytherapy-unsuitable cervical cancer patients – a preliminary result

Hsieh CH, Tien HJ, Hsiao SM, Wei MC, Wu WY, Sun HD, Wang LY, Hsieh YP, Chen YJ, Shueng PW

OncoTargets and Therapy 2013, 6:59-66

Published Date: 4 February 2013

Retraction

Singhai R

Breast Cancer: Targets and Therapy 2012, 4:33-34

Published Date: 8 March 2012